Form 4: Kairos Pharma Executive Acquires 14,000 Restricted Stock Units

Neil Bhowmick, Chief Scientific Officer of Kairos Pharma, Ltd., reports the acquisition of 14,000 restricted stock units (RSUs) under the company's 2023 Equity Incentive Plan.

Summary

• Neil Bhowmick, the Chief Scientific Officer of Kairos Pharma, Ltd., filed a Form 4 on April 7, 2025, reporting changes in beneficial ownership.
• The report details the acquisition of 14,000 restricted stock units (RSUs) on January 1, 2025, under the company's 2023 Equity Incentive Plan.
• These RSUs were granted at a price of $0.00.
• As of the report, Mr. Bhowmick beneficially owns 1,139,983 shares of common stock, including vested and unvested RSUs.
• 4,667 of the 14,000 RSUs vested on January 1, 2025.
• The remaining RSUs are scheduled to vest in two tranches on September 16, 2025, and September 16, 2026.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to executive compensation. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The granting of RSUs to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company's success.

Future Outlook

The document does not contain specific forward-looking statements beyond the RSU vesting schedule.

Industry Context

Form 4 filings are a standard part of regulatory compliance for company insiders, providing transparency into their transactions in the company's securities. This filing indicates standard executive compensation practices.

Comparison to Industry Standards

• Equity compensation is a common practice in the pharmaceutical industry to attract and retain key personnel.
• RSUs are a typical form of equity compensation, vesting over time to incentivize long-term commitment.
• Vesting schedules of one-third increments annually or bi-annually are standard in the industry.
• Similar companies like Amgen, Gilead Sciences, and Biogen use equity incentive plans as part of their compensation packages.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see the equity incentive plan as a benefit, potentially boosting morale.

Key Dates

Keywords

Form 4, beneficial ownership, restricted stock units, RSUs, Kairos Pharma, Bhowmick, equity incentive plan, vesting